Key Points {#FPar1}
==========

Evolution in regulatory approaches and innovation by developers are enabling price-competitive products to reach patients more quickly without compromising safety and efficacy standards.Pharmacoeconomic assessments need to be revisited following biosimilar market entry to remove nonmedical barriers to accessing biologic treatments, when clinically appropriate, and effective physician communication is crucial to support patient confidence in biosimilars.Achieving the full potential benefits of biosimilars to deliver cost savings and expanded patient access requires the efforts of, and efficient collaboration among, multiple stakeholders.

Introduction {#Sec1}
============

Biosimilars are biologic medicines that have no clinically meaningful differences from originator biologics (reference products \[RPs\]) that have already received regulatory approval. RPs have proven efficacy across many disease states and have revolutionized the treatment of immune-mediated inflammatory diseases (IMIDs), including rheumatic diseases, such as rheumatoid arthritis (RA), and inflammatory bowel disease (IBD) \[[@CR1]--[@CR3]\]. Multiple biosimilars have been licensed by the European Medicines Agency (EMA) and the United States (US) Food and Drug Administration (FDA) for the treatment of RA and IBD (Fig. [1](#Fig1){ref-type="fig"}), and an estimated 240 biosimilar candidates are in development across all diseases \[[@CR4]\]. Clinical experience with biosimilars is growing, currently exceeding 700 million patient-days \[[@CR5]\], and biosimilar uptake is increasing globally \[[@CR6]--[@CR8]\]. As an example, in 2017, infliximab and etanercept biosimilars held 79% and 54% of the UK market share, respectively \[[@CR7]\].Fig. 1Biologics licensed by the FDA and/or EMA for the treatment of RA and/or IBD as of 25 November 2019 (references are provided in Table S2 in the electronic supplementary material). TNF inhibitors are shown in black; biologics with other targets are shown in gray. For biologics shown in **bold**, biosimilars have been licensed by the FDA and/or the EMA in relevant indications. ^a^Licensed by the FDA only. ^b^Licensed by the FDA only for the treatment of Crohn's disease. ^c^The intravenous form of golimumab (Simponi Aria^®^) is licensed by the FDA only, for the treatment of RA only. *EMA* European Medicines Agency, *IBD* inflammatory bowel disease, *RA* rheumatoid arthritis, *TNF* tumor necrosis factor

The reduced cost of biosimilars relative to RPs can drive market competition, contributing to budget sustainability and improving patient access to biologic treatments. Substantial cost savings attributable to biosimilars have been projected globally, with one recent estimate suggesting that direct spending on biologics could be reduced by \$US54 billion in the USA from 2017 to 2026 because of biosimilars \[[@CR9]\]. In the European Economic Area, biosimilar competition has already reduced average list prices and increased patient access to biologics \[[@CR10]\]. Growing real-world evidence with biosimilars \[[@CR11]--[@CR13]\] is helping to support clinical use, increasing confidence in biosimilars. However, many patients are still treated with RPs, partly because of ongoing physician and patient concerns about biosimilars.

In this article, we aim to draw on our broad collective backgrounds to summarize our diverse, current perspectives on the future of biosimilars in IMIDs, focusing on RA and IBD. We also identify obstacles to widespread uptake of biosimilars and discuss approaches to help ensure that the benefits of biosimilars for healthcare systems and patients are maximized in the future.

Regulators' and Pharmacologists' Perspective: Rigorous and Efficient Development of Biosimilars {#Sec2}
===============================================================================================

Regulatory approval of biosimilars is based on the totality of evidence supporting comparability of the proposed biosimilar and RP \[[@CR14]\]. During biosimilar development, the quality attributes (structural, functional, and other analytical properties) of the RP must first be defined. The range of variation for any attribute directly impacting on the efficacy or safety of the RP (a "critical quality attribute") must be carefully measured using multiple drug batches: these are used to define the quality target product profile of the proposed biosimilar \[[@CR15]--[@CR17]\]. For example, the critical quality attributes of infliximab, the RP for biosimilar CT-P13, are numerous and include those related to structure (primary and higher-order structures, glycosylation profiles), biological function (receptor-binding affinity, cytotoxicity), content (protein concentration), and impurities (host cell protein or DNA) \[[@CR15]\].

Manufacturing processes for biosimilars must effectively be "reverse engineered" as details for RPs are not publicly available. Selection of the expression system (cell line and expression construct) is a pivotal decision as this can affect biosimilar translational and post-translational modifications and determine the number and nature of product impurities and contaminants \[[@CR18]\]. Cell culture and product-purification processes must be gradually refined until the product possesses the target profile \[[@CR15], [@CR17]\]. Manufacturing processes must then be validated and carefully controlled to ensure consistent manufacture of a biosimilar candidate with this profile \[[@CR15]\].

Demonstrating biosimilarity warrants a step-wise approach (moving from analytical analyses through nonclinical studies to clinical trials) as recommended by regulatory bodies such as the EMA and FDA \[[@CR19], [@CR20]\]. Analytical analyses account for most of the effort involved in biosimilar development \[[@CR21], [@CR22]\], with the combination of multiple orthogonal, state-of-the-art methodologies allowing a highly sensitive determination of the degree of similarity in critical quality attributes between the proposed biosimilar and the RP \[[@CR14], [@CR23]\]. However, current methodologies cannot provide all desirable information regarding biosimilarity at the nonclinical stage. For example, techniques to investigate how differences in post-translational modifications such as glycosylation might impact on the three-dimensional protein structure, and thus function, are lacking \[[@CR24]\], although advances in areas such as mass spectrometry may address such issues in the future \[[@CR25]\].

Any differences (inevitably) detected in nonclinical analyses must be demonstrated to be not clinically meaningful, with the extent and type of clinical data required for approval depending on the nature of remaining uncertainties regarding biosimilarity \[[@CR20]\]. Therefore, unlike clinical trials for new drugs, biosimilar clinical trials are designed to establish pharmacokinetic and efficacy equivalence to the RP and to demonstrate that the proposed biosimilar and RP share similar pharmacodynamic, immunogenicity, and safety profiles \[[@CR14], [@CR17]\]. EMA guidelines, which are in line with FDA principles, generally recommend that biosimilar trials include a head-to-head comparison of pharmacokinetics and pharmacodynamics, followed by at least one adequately powered, randomized, parallel-group, head-to-head comparison of efficacy and safety \[[@CR14], [@CR19], [@CR20]\]. Equivalence, rather than noninferiority, studies are usually required to establish that the proposed product is neither inferior nor superior to the RP \[[@CR19], [@CR20]\]. However, noninferiority studies may be suitable in some scenarios, such as when the RP dose is close to saturating the target \[[@CR20]\]. Prespecified, typically symmetrical, two-sided equivalence margins or one-sided noninferiority margins must be calculated considering the variability in historical data for the RP: the margin reflects clinically acceptable differences in efficacy \[[@CR26], [@CR27]\]. The sample size should be adequate to detect clinically meaningful differences between biosimilar and RP and may be smaller in a noninferiority study than in an equivalence study \[[@CR20]\]. Unlike superiority trials, per-protocol analysis is preferred for equivalence or noninferiority trials since it is more conservative than intention-to-treat analysis \[[@CR28], [@CR29]\].

The study population recruited into a biosimilar efficacy clinical trial should be generally aligned with one or more approved indication of the RP and should be the most sensitive for detecting any potential differences between the two drugs \[[@CR19], [@CR20]\]. However, while psoriasis represents a sensitive disease model to detect potential differences in clinical efficacy and immunogenicity between adalimumab biosimilars and the RP, ongoing pivotal studies more frequently include patients with RA, perhaps reflecting both patient population size and the potential commercial impact of RA \[[@CR30]\]. In ulcerative colitis (UC), high and variable placebo response rates \[[@CR31], [@CR32]\] may also present a challenge for selection of this indication for biosimilar trials. The endpoints used in biosimilar clinical trials should be appropriate and sensitive enough to detect potential differences between the RP and the proposed biosimilar \[[@CR19], [@CR20]\]. Considering CT-P13 evaluation in IMIDs, multiple endpoints were evaluated during the PLANETRA equivalence study, including Disease Activity Score in 28 joints (DAS28), based on C-reactive protein (CRP), and American College of Rheumatology and European League Against Rheumatism (EULAR) response rates; the endpoints were highly similar between CT-P13 and reference infliximab at week 30 \[[@CR33]\]. The postmarketing phase III PLANETCD study comparing CT-P13 and reference infliximab in patients with Crohn's disease (CD) used a Crohn's Disease Activity Index-based primary endpoint \[[@CR34]\], whereas two cohort studies comparing these agents in patients with either CD or UC employed composite primary endpoints (comprising death, CD-related surgery, all-cause hospitalization, and reimbursement for other biologics) \[[@CR35], [@CR36]\]. The sensitive endpoints of endoscopic remission/mucosal healing were also employed in the PLANETCD study as a tertiary efficacy endpoint \[[@CR34]\] and have been assessed in prospective observational studies of CT-P13 treatment in patients with UC \[[@CR37]--[@CR41]\].

Intrinsic to the clinical safety and efficacy assessment of biosimilars is evaluation of immunogenicity, as detailed in FDA and EMA guidelines \[[@CR20], [@CR42]\]. Anti-drug antibodies (ADAs) may affect biologic efficacy by modulating pharmacokinetics for example, or adversely affect safety, with consequences including infusion-related reactions and serum sickness \[[@CR43], [@CR44]\]. Multiple factors contribute to the risk of immunogenicity, including post-translational modifications such as glycosylation, as discussed in a recent review \[[@CR43]\]. Although the authors noted that glycosylation is a common area of divergence between biosimilars and RPs, this has not led to discrepancies in immunogenicity for any EMA-approved biosimilar \[[@CR43]\]. Immunogenicity assay development and validation must follow a rigorous process, in line with the detailed regulatory guidance \[[@CR45], [@CR46]\]. With multiple approaches possible, different technologies should be compared to ensure assay suitability, as conducted for CT-P13 \[[@CR47]\]. However, debate continues regarding optimal assay design, with variations in assays used leading to extensive variability in reported immunogenicity and posing a challenge for interstudy comparability \[[@CR48], [@CR49]\]: for infliximab treatment, a recently published systematic review highlighted that reports of ADA-positive patients ranged from 0 to 65.3% \[[@CR50]\].

Alongside the difficulties for immunogenicity assays, selection of appropriate pharmacodynamic markers for some biologics may be challenging because of ambiguities in their mechanism of action. For example, the complexity of tumor necrosis factor (TNF) signaling means that the mechanisms of action of TNF inhibitors are still poorly understood, particularly in IBD \[[@CR51]\], compared with the relatively well-characterized depletion of cluster of differentiation 20-positive (CD20+) B cells underlying rituximab efficacy in RA \[[@CR52]\]. This warrants the use of multiple pharmacodynamic markers in clinical studies evaluating TNF inhibitors, with targets, assay types, and methodologies considered on a case-by-case basis. In RA, an approach combining the evaluation of biomarkers representing immune and inflammatory processes (rheumatoid factor and anticyclic citrullinated peptide, and CRP and erythrocyte sedimentation rate, respectively \[[@CR53]\]) may be required.

While regulatory agency guidelines on biosimilar development are broadly aligned scientifically and recommend the step-wise performance of analytical, nonclinical, and clinical studies, agencies vary in requirements and, sometimes, in their interpretations of the same data (Table [1](#Tab1){ref-type="table"} \[[@CR54], [@CR55]\]). For example, the FDA requires at least one clinical pharmacokinetic study including the version of the RP licensed in the USA, whereas Swissmedic, the Swiss regulatory agency, prefers that comparability studies use the RP from Switzerland, and Health Canada provides additional guidance for developers selecting a non-Canadian RP \[[@CR20], [@CR56], [@CR57]\]. Regulatory agencies may also require studies supporting extrapolation of clinical data to patients of different ethnicities. For example, for the Japanese regulatory authority to consider efficacy and safety data from the global multicentre PLANETRA study \[[@CR33]\], a bridging study comparing the pharmacokinetics, efficacy, and safety of CT-P13 and reference infliximab was performed in Japanese patients with RA, followed by an extension study evaluating the safety of CT-P13 during long-term treatment or after switching from reference infliximab \[[@CR58], [@CR59]\]. It is worth noting that geographical variations in regulatory requirements may contribute to the reluctance of some physicians to fully adopt biosimilars in clinical practice, alongside concerns surrounding indication extrapolation, as exemplified in IBD \[[@CR3]\] and discussed later in Sects. [4](#Sec4){ref-type="sec"} and [7](#Sec7){ref-type="sec"}.Table 1US FDA and EMA requirements for data supporting biosimilar approval \[[@CR19], [@CR20], [@CR190]\]Type of data^a^US FDAEMAStructural and analytical studies✓✓Functional assays^b^✓✓In vivo toxicology✓Dependent on in vitro findingsClinical pharmacokinetic study✓^c^✓Clinical immunogenicity assessment✓✓Clinical efficacy and safety trialsRequired in the absence of surrogate pharmacokinetic markers for efficacyClinical switching studyRequired to demonstrate interchangeability^d^✘*EMA* European Medicines Agency^a^In all cases, data should be collected in a comparative fashion between the proposed biosimilar and the reference product^b^The FDA states that the functional assays can be in vitro and/or in vivo, whereas the EMA requires in vitro functional assays^c^The FDA requires at least one clinical pharmacokinetic study to compare the proposed biosimilar with the version of the reference product licensed in the USA^d^Switching studies are not required for the FDA biosimilar approval pathway per se. However, one or more switching studies would generally be required as part of a demonstration of interchangeability. These studies should evaluate changes in treatment resulting from two or more alternating exposures to the reference product and the proposed interchangeable biosimilar

Regulatory agencies recommend that biosimilar manufacturers align their development strategies with each agency's specifications and hold discussions with the agencies before and during the development of each biosimilar \[[@CR60]--[@CR62]\] to minimize inefficiencies and delays. A robust biosimilar development plan should include strategies to ensure that, after biosimilar approval, the clinical safety of the product is appropriately monitored and any potential shortages in drug supply are prevented \[[@CR63], [@CR64]\]. Proper management of the biosimilar supply chain is vital to avoid product shortages, which could compromise patient safety and clinical outcomes, and might be caused by manufacturing issues, delays in supply, or other disruptions \[[@CR64]\]. The EMA requires that descriptions of a risk management plan and pharmacovigilance system be included in any application for biosimilar approval, capturing risks and any specific monitoring associated with the RP \[[@CR19], [@CR65]\]. In the USA, as for any medication, the FDA may request that a risk evaluation and mitigation strategy is established for approved biosimilars \[[@CR66]\].

Biosimilar developers should be mindful of possible future changes in approval pathways, as regulatory agencies aim to streamline and accelerate development and review processes for medical products, for example via the US 21st Century Cures Act \[[@CR67], [@CR68]\].

Rheumatologists' Perspective: Improved Access by Addressing Disparities in Reimbursement Criteria {#Sec3}
=================================================================================================

RA treatment aims to achieve tight disease control (long-term low disease activity or remission), thereby preventing irreversible joint damage, maximizing long-term health-related quality of life, and reducing long-term societal costs \[[@CR69]--[@CR72]\]. To accomplish this, early diagnosis and treatment are essential; however, striking the right balance between clinical benefits, risks, and economic considerations can be challenging.

Biologics have transformed the treatment of the rheumatic diseases, including RA, psoriatic arthritis, and ankylosing spondylitis (AS) \[[@CR1], [@CR2]\]. In recent years, RA treatment guidelines have proliferated, given the increasing cost of management in the biologic era. Current guidelines recommend access to biologics based on disease duration, disease severity, and number of insufficient responses to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) \[[@CR69]--[@CR76]\], although differences in expert opinion may lead to divergent interpretations of the same evidence between guidelines. In addition, high costs and poor affordability often restrict patient access to biologics \[[@CR77]--[@CR81]\], alongside factors such as prescription controls and limitations in access to healthcare services \[[@CR81]\]. Furthermore, national reimbursement criteria can be more restrictive than treatment guidelines, leading to disparities in patient access to biologics among countries \[[@CR77], [@CR82]\]. For example, a recent study in the European region (defined as 37 European countries, plus Russia and Turkey) found that only 59% of patients eligible for biologics according to EULAR guidelines (DAS28 \> 3.2 and ≥ 2 csDMARD treatment failures) remained eligible following application of national reimbursement criteria \[[@CR79]\]. The analysis also found that 16 of 39 countries required DAS28 \> 5.1 for reimbursement \[[@CR79]\], restricting biologics to patients with high disease activity and limiting the ability of rheumatologists to effectively implement a treat-to-target approach. Indeed, persistently moderate elevation of DAS28 has been associated with functional deterioration in some patients \[[@CR83]\], whereas evidence confirming the efficacy of TNF inhibitors in patients with moderate disease activity (DAS28 \> 3.2 to ≤ 5.1) is emerging from studies solely evaluating this population \[[@CR84]\]. In general, low socioeconomic status of a country is linked to stricter reimbursement criteria, although UK criteria are notably more restrictive than this would suggest \[[@CR77], [@CR80]--[@CR82]\]. Biosimilars present the opportunity for more cost-effective biologic treatment, which should help to address the disparities in patient access imposed by stringent national reimbursement criteria that may diverge from clinical guidelines.

Gastroenterologists' Perspective: Earlier Introduction of Biologics for Better Clinical Outcomes {#Sec4}
================================================================================================

IBD treatment aims to change the natural history of the disease, thereby avoiding tissue damage and disability \[[@CR85]\]. This requires prompt, early treatment and implementation of a treat-to-target approach (top-down or accelerated step-up) to achieve objective endpoints such as endoscopic remission \[[@CR86]--[@CR91]\]. Consequently, treatment paradigms are changing to introduce biologics and/or immunomodulators at an earlier stage of disease \[[@CR87], [@CR90], [@CR92]--[@CR95]\]. Numerous guidelines address the role of biologics in IBD treatment \[[@CR96]--[@CR102]\], generally recommending biologics as a treatment option for steroid-refractory/dependent disease or in patients who are intolerant of, or have contraindications to, conventional therapy. Early treatment with biologics is recommended in certain patient populations, including those with a poor prognosis or extensive or severely active disease \[[@CR96], [@CR97], [@CR103]\].

A "window of opportunity" exists in patients with CD, during which intervention with disease-modifying anti-IBD drugs should occur \[[@CR104]\] and TNF inhibitor treatment can be much more effective than later use \[[@CR93]\]. Available data on early IBD treatment with TNF inhibitors are summarized in Table S1 in the electronic supplementary material. For infliximab, studies in pediatric patients have reported that early treatment is associated with improved clinical outcomes, including a reduced rate of relapse and increased mucosal healing \[[@CR105]--[@CR107]\]. The CHARM trial in adalimumab-treated patients with moderate-to-severe CD found the highest remission rates and lowest side effects in the shortest disease duration subgroup (\< 2 years) \[[@CR108]\]. Early treatment escalation to adalimumab in the CALM trial resulted in a significantly higher proportion of patients achieving endoscopic, steroid-free, and clinical remission versus clinical management, with a similar incidence of treatment-emergent adverse events \[[@CR109]\]. Early versus late treatment is also associated with improved outcomes in retrospective analyses of TNF inhibitor-treated patients with CD \[[@CR110]--[@CR113]\]. Benefits of early vedolizumab treatment have also been described \[[@CR114]--[@CR116]\].

Biosimilars were first licensed for IBD treatment in 2013, with EMA approval of CT-P13 across all infliximab indications \[[@CR117]\]. Several infliximab and adalimumab biosimilars have subsequently been approved by the EMA and the FDA, with more in the pipeline \[[@CR118], [@CR119]\]. To date, approval of biosimilars for the treatment of IBD has been based on "extrapolation," where approval is permitted in licensed indications of the RP beyond those evaluated in biosimilar clinical trials \[[@CR3]\]. For extrapolation to be permitted, biosimilarity must have been demonstrated in in vitro, nonclinical, and clinical studies, and the rationale for extrapolation must be scientifically justifiable \[[@CR3]\]. Today, approval of CT-P13 in IBD is also supported by real-world evidence and clinical trial data \[[@CR34], [@CR120]--[@CR123]\], including from the randomized, double-blind, noninferiority phase IV NOR-SWITCH study \[[@CR120]\] and a Hungarian prospective observational cohort study \[[@CR124]\]. To our knowledge, no published clinical trials evaluating the approved adalimumab biosimilars ABP 501, BI 695501, or SB5 in IBD, or real-world evidence for other infliximab biosimilars exist. All three adalimumab biosimilars have demonstrated pharmacokinetic similarity to the RP in equivalence studies in healthy subjects \[[@CR125]--[@CR127]\] and similar efficacy and safety in clinical trials in patients with RA \[[@CR128]--[@CR130]\].

Pharmacoeconomists' Perspective: Cost of and Access to Biologic Therapy Reframed by Biosimilars {#Sec5}
===============================================================================================

Biologics represent a significant cost for both RA and IBD treatment, with high costs limiting patient access. However, patent expiration of biologics has enabled development of lower-cost biosimilars, leading to increased market competition and price reductions \[[@CR7]\]. In RA, initial pharmacoeconomic analyses suggested poor cost-effectiveness of TNF inhibitors versus csDMARDs in patients naïve or with an insufficient response to csDMARDs \[[@CR131]\]. However, these analyses were performed before biosimilar market entry, missing the impact of biosimilars on price competition and consequent reduced treatment costs and expanded patient access \[[@CR132]\]. Biosimilars, market competition, and price reductions improve the cost-effectiveness of biologic therapy in RA. In IBD, existing data support the potential for biosimilars to deliver cost savings and improve patient access to biologics \[[@CR133], [@CR134]\], and cost-effectiveness analyses are expected to be continuously updated. The cost-effectiveness of early biologic treatment in IBD is also being explored \[[@CR135]\], whereas a model extrapolating data from the CALM trial in CD showed that "tight control," using biomarkers to direct adalimumab treatment, was cost-effective versus standard clinical management over 2- and 5-year timeframes, with cost-effectiveness improving over time \[[@CR136]\].

Biosimilar uptake may also bring indirect economic benefits, often not considered in cost-effectiveness analyses \[[@CR137]\]. In RA, effective early treatment with DMARDs \[[@CR138]\] or biologics \[[@CR139]\] can improve workforce productivity, with economic benefits for individuals and society. Future cost-effectiveness analyses should endeavor to be as accurate as possible, incorporating the most relevant information, and be updated regularly; the importance of revisiting economic analyses following oncology biosimilar availability has been noted \[[@CR140]\]. Inaccurate pricing information could lead to unfavorable cost-effectiveness estimates, restricting patient access to treatment.

Budget impact analyses have predicted that biosimilar uptake could generate significant cost savings, reduce the cost of illness, and increase patient access \[[@CR141], [@CR142]\]. One analysis suggested that the introduction of CT-P13 in six European countries could deliver net savings of €15.3 million over 3 years, increasing to €20.8 million if 80% of infliximab-treated patients also switched \[[@CR143]\]. Such cost savings must be balanced against potential budget increases from expanding patient access to biologics and providing additional services for patients \[[@CR78], [@CR144]\]: in the aforementioned analysis, the cost savings from CT-P13 uptake could be used to treat an additional 1200--1800 patients over 3 years \[[@CR143]\]. Cost savings may also enable earlier access to biologics in some countries \[[@CR145], [@CR146]\]. If cost savings were directed toward additional services, therapeutic drug monitoring (TDM) could help optimize TNF inhibitor therapy and deliver personalized care for patients with IBD \[[@CR147], [@CR148]\]. TDM involves measurement of drug and ADA levels: ADA formation is frequently associated with reduced primary efficacy and loss of response to IBD treatment \[[@CR50]\] and may be predicted by factors including drug clearance and body weight \[[@CR149]\]. Proactive TDM may be beneficial for longer-term outcomes \[[@CR150]\]. However, the TAXIT and TAILORIX trials did not identify any benefit on clinical remission rates, although factors including the high incidence of dose intensification in the TAILORIX clinical care group may explain this \[[@CR151], [@CR152]\]. Currently, proactive TDM is performed in limited numbers of patients with IBD receiving TNF inhibitors \[[@CR147]\] and is not widely recommended unless likely to impact on clinical management, although cost-effectiveness analyses demonstrate its benefits \[[@CR153]\]. In addition, the increased affordability of biosimilars relative to biologics could facilitate clinical research incorporating these agents.

Predicted cost savings from biosimilar uptake are borne out in real-world experience. In the 2017--2018 financial year, the UK National Health Service saved £324 million through switching to biosimilars or generics for ten medicines, with almost £100 million saved through uptake of infliximab biosimilars \[[@CR154]\]. Similarly, an analysis of rheumatology specialties in the UK (2014--2017) found that £38.8 million was saved over 2 years following the introduction of infliximab and etanercept biosimilars, because of biosimilar uptake and RP price reductions \[[@CR155]\]. In Scandinavian countries, biosimilar availability has heralded significant cost savings and expanded patient access to biologics, despite already high use \[[@CR10], [@CR132]\]. In Norway, most patients with newly diagnosed IBD have received biosimilar infliximab since 2014, and, more recently, patients receiving infliximab maintenance therapy have switched to biosimilar infliximab \[[@CR156]\]: following the introduction of infliximab biosimilars, patient access increased and expenditure reduced \[[@CR132]\]. A mandatory switch to biosimilar infliximab for IBD induction and maintenance therapy has also been partially implemented in Norway, Poland, and the UK \[[@CR157]\], and France aims to reach 80% biosimilar penetration by 2022, partly through switching RP-treated patients \[[@CR158]\].

Evidence suggests no safety or efficacy concerns with a single switch from RP to biosimilar in IBD or RA \[[@CR12], [@CR34], [@CR120], [@CR159], [@CR160]\]. For example, in biologic-naïve patients with CD, safety and efficacy were similar over 54 weeks for patients receiving reference infliximab throughout, CT-P13 throughout, or switching to the other agent at week 30 \[[@CR34]\]. Furthermore, there was no clinically meaningful difference in the proportion of ADA-positive patients between groups; the proportion of neutralizing antibody-positive patients was also similar \[[@CR34]\]. However, data regarding the economic impact and healthcare resource use of nonmedical switching are limited, as highlighted in a recent systematic literature review that identified few studies using real-world estimations and methodological shortcomings in others \[[@CR161]\]. Any increase in direct financial or healthcare professional (HCP) time costs related to switching patients could present an obstacle to biosimilar uptake. Data from the DANBIO registry of patients with inflammatory rheumatic disease demonstrated that a mandatory switch from reference infliximab to CT-P13 resulted in only minor changes to outpatient healthcare resource use \[[@CR11]\], whereas a recent study found that the modest cost savings offered by biosimilar etanercept did not justify the additional workload involved in actively switching patients from the RP in some Swedish counties \[[@CR162]\]. Data regarding single switches are accumulating, but, to our knowledge, no published studies have investigated cross-switching (between two biosimilars) or multiple/repeated switches in RA or IBD \[[@CR159], [@CR163], [@CR164]\] with regard to efficacy, safety, or cost considerations. However, evidence regarding multiple switching is emerging in psoriasis, with no impact on efficacy, safety, or immunogenicity detected after up to four switches between reference adalimumab and GP2017 \[[@CR165]\] or up to three switches between reference etanercept and GP2015 \[[@CR166]\]. Nevertheless, future studies should cautiously assess multiple and cross-switches in patients with other IMIDs; the pharmacoeconomic implications remain to be determined.

Patients' Perspective: Improved Information Sharing May Encourage Greater Acceptance of Biosimilars {#Sec6}
===================================================================================================

Successful biosimilar uptake requires that patients understand the rationale for, and have any concerns allayed about, initiating or switching to biosimilars. Indeed, the European Crohn's and Colitis Organisation (ECCO) advocates that patients must be fully informed to allow evidence-based patient choice, and that such communication must consider patient health literacy \[[@CR159]\]. ECCO notes that HCPs must transparently communicate "the tangible benefits of the biosimilar product" to patients, and that nurses can play a crucial role \[[@CR159], [@CR167]\]. However, reported patient awareness and understanding of biosimilars varies. A 2014--2015 European survey of 1059 patients with IBD found that approximately 36% had heard of biosimilars \[[@CR168]\], and 49% of Belgian patients with RA (surveyed in 2016) reported familiarity with biosimilars \[[@CR169]\]. In a 2017 UK survey of patients with RA and AS, 66% and 80% of respondents receiving RPs or biosimilars, respectively, understood what biosimilars were \[[@CR170]\]. Among European patients with IBD who had heard of biosimilars, safety and efficacy were the most common concerns (47% and 39%, respectively), whereas around one-quarter of respondents had no specific concerns \[[@CR168]\]. Furthermore, patients with autoimmune conditions expressed concerns that nonmedical switching could influence treatment outcomes \[[@CR171]\].

Patients may experience nocebo effects (worsening or incitement of symptoms that are induced by a negative attitude toward an intervention) \[[@CR172]\] that are only perceptible to the patient \[[@CR173]\] and may impact on quality of life, treatment adherence, and the cost-saving potential of biosimilars \[[@CR172], [@CR174]\]. In a study of 100 patients with RA, AS, or psoriatic arthritis, 89% initially accepted a nonmedical switch from reference infliximab to CT-P13 \[[@CR175]\]. However, 28% of patients requested a re-switch to reference infliximab, 44% of whom had no worsening of disease activity, suggesting that negative perceptions about biosimilars affected retention rates \[[@CR175]\]. Another study of 125 patients with IBD or rheumatic disease found that 12.8% experienced a nocebo response following a nonmedical switch from RP to biosimilar infliximab \[[@CR176]\]; in the DANBIO registry, subjective reasons mainly accounted for back-switching from biosimilar to reference etanercept \[[@CR13]\]. Nocebo responses to biosimilars may be triggered by multiple interacting patient-related factors and psychological mechanisms influenced by both information provided to patients and the therapeutic environment \[[@CR174]\]. Experiences shared by patients, as well as media coverage and results of internet searches, may also influence perceptions of biosimilars, contributing to nocebo effects \[[@CR174]\]. Considering nocebo effects in patient--HCP communication may help to minimize the nocebo effect experienced and improve outcomes \[[@CR174]\]. HCPs can minimize biosimilar-related nocebo effects through being well-informed and confident, facilitating shared, informed decision making with patients \[[@CR177]\]. Positive framing, contextualized informed consent, and unified communications can also reduce nocebo effects \[[@CR172], [@CR174]\]. Despite the increasing use of internet health information by patients, one survey found that perceived physician quality had a greater impact on treatment compliance than the perceived quality of internet health information \[[@CR178]\], emphasizing the importance of HCP communication. In addition, educational materials developed by medical societies or government organizations, in conjunction with patient groups, could play a key role in supporting patient education about biosimilars, as recognized in the oncology setting \[[@CR179]\].

Developers' Perspective: Innovative Approaches to Bring Additional Value {#Sec7}
========================================================================

Developers must minimize concerns about clinical outcomes and long-term performance of biosimilars through the generation, publication, and distribution of data appropriate for stakeholders, including physicians, patients, and payers, beyond that required for regulatory approval \[[@CR180]--[@CR182]\]. Educational activities and publication of data in respected medical journals can help to build trust and familiarity with biosimilars among physicians \[[@CR183]\]. For example, an evidence-based approach helped to alleviate physicians' concerns about indication extrapolation and switching from reference infliximab to CT-P13 in the treatment of IBD \[[@CR184], [@CR185]\], perhaps contributing to a change in ECCO's position on biosimilars \[[@CR159]\]. Additional analyses of clinical data, reflecting medical society guidelines, can be conducted to support biosimilar use. For example, efficacy analyses in different patient subgroups and analysis populations, and implementation of alternative statistical techniques for handling missing data, were reported from the extension phases of the CT-P13 PLANETRA and PLANETAS studies \[[@CR160], [@CR186]\]. To aid the understanding of some stakeholders, including patients and payers, publications can be translated into local languages or data can be effectively communicated using lay summaries.

As more biosimilars arrive on the market, competition will push prices down \[[@CR7]\]. Developers and payers should align pricing and market access policies to support a sustainable biosimilar market, where developers' investments are balanced by a fair price and healthy competition is encouraged \[[@CR144]\]. Companies must be efficient, not only at the production level but across the entire process from research and development to distribution, to maintain sustainability in the long term. Beneficially, the ability to extrapolate the clinical use of biosimilars to other indications minimizes drug development and regulatory approval costs \[[@CR117]\]. Gains from biosimilar development could also be extended through the use of innovative approaches, such as the development of more convenient or longer-acting drug formulations, as conducted by RP manufacturers \[[@CR7]\]. For example, infliximab biosimilars are currently administered intravenously, but a subcutaneous formulation of CT-P13 that could offer increased convenience for patients is in development \[[@CR187]--[@CR189]\]. Adding value to a product and dedication to an evidence-based approach will be key factors in determining the future success and sustainability of a developer in the competitive biosimilars market.

Conclusions {#Sec8}
===========

The cost savings generated by biosimilar uptake could enable improved patient access to biologic treatments for those in need. However, to maximize gains from biosimilar uptake, each stakeholder must fulfill their responsibilities as efficiently as possible. While the advent of biosimilars required regulators to adopt new frameworks, past and ongoing evolution in their scientific approach to biosimilar regulation is helping to minimize development time and investment required for biosimilar approval. This enables biosimilars to reach patients more quickly, without compromising safety and efficacy standards. Payers should revisit pharmacoeconomic assessments to ensure they reflect the impact of biosimilar market entry to relieve nonmedical barriers to biologic treatment for patients. Physicians should improve their understanding of biosimilars, increasing their confidence in prescribing biosimilars in line with treatment and healthcare funder guidelines to maximize cost savings. Patients and physicians must recognize the potential for nocebo effects. Physician communication strategies should be improved to limit the impact of nocebo effects on clinical outcomes and treatment discontinuation, to improve patient experiences, and to realize the cost-saving potential of biosimilars. Developers must be efficient to minimize costs and be price competitive without undermining product quality, the sustainability of supply, or pharmacovigilance systems. Additional innovation might be required for a product to be competitive in the context of multiple approved biosimilars. Developers should diligently provide data to meet the requirements of each stakeholder. In summary, all stakeholders must collaborate efficiently to realize the ultimate goal of biosimilar development: delivering the clinical benefits of biologic therapy to patients without sacrificing the sustainability of the healthcare system.
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